Showing results (1401-1410 of 2,389) with videos related to
Sort By:
Pageof 239
Digestive Diseases (Basel, Switzerland)|October 18, 2016
Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular CarcinomaTadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, et al.Digestive Diseases (Basel, Switzerland)|October 18, 2016
Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial ChemoembolizationToshihiko Kawasaki, Kan-Yun Hata, Daisuke Kinoshita, et al.Digestive Diseases (Basel, Switzerland)|October 18, 2016
Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENTChikara Ogawa, Yasunori Minami, Masahiro Morita, et al.Digestive Diseases (Basel, Switzerland)|February 2, 2017
Leukocyte Anti-Trafficking Strategies: Current Status and Future DirectionsBruce E SandsDigestive Diseases (Basel, Switzerland)|February 2, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases CentreM Kolar, D Duricova, M Bortlik, et al.Digestive Diseases (Basel, Switzerland)|February 2, 2017
Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art TreatmentC J HawkeyDigestive Diseases (Basel, Switzerland)|February 2, 2017
What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?Jacques CosnesDigestive Diseases (Basel, Switzerland)|February 2, 2017
Mesenchymal Stromal Cell Therapy in Crohn's DiseaseGeoffrey M ForbesDigestive Diseases (Basel, Switzerland)|February 2, 2017
Real-Life Efficacy, Immunogenicity and Safety of Biosimilar InfliximabZsuzsanna Vegh, Zsuzsanna Kurti, Peter L LakatosDigestive Diseases (Basel, Switzerland)|February 2, 2017
Crohn's Disease and Intestinal TransplantationPavel Drastich, Martin OliveriusPageof 239